Mohammad Javad Nasiri

Dr. Mohammad Javad Nasiri

Department of Microbiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
APAli Pormohammad
Ali Pormohammad
Mohammad Javad NasiriMohammad Javad Nasiri
Mohammad Javad Nasiri
TATaher Azimi
Taher Azimi
Background: Antimicrobial resistance is a serious public health problem worldwide. We aimed to investigate the prevalence of antibiotic resistance in Escherichia coli strains simultaneously isolated from humans, animals, food, and the environment. Methods: Studies on PubMed, Embase, and the Cochrane Library published from January 1, 2000 to January 1, 2018 were searched. The quality of the included studies was assessed by the modified critical appraisal checklist recommended by the Joanna Briggs Institute. All analyses were conducted using Biostat’s Comprehensive Meta-Analysis version 2.0. Depending on the heterogeneity test for each antibiotic, we used a random- or fixed-effect model for pooled prevalence of drug resistance. Studies were eligible if they had investigated and reported resistance in two or more isolation sources (human, animal, food, or environment). To decrease heterogeneity and bias, we excluded studies that had reported E. coli drug resistance isolated from one source only. We included publications that reported drug resistance with minimum inhibitory concentration or disk diffusion method (DDM) as antibiotic-susceptibility tests. Results: Of the 39 included studies, 20 used the DDM and 19 minimum inhibitory concentration for their antibiotic-susceptibility testing. Colistin had the lowest prevalence, with 0.8% (95% CI 0.2%–3.8%) and amoxicillin the highest, with 70.5% (95% CI 57.5%–81%) in isolated human E. coli strains tested with the DDM. To assess historical changes in antimicrobial drug resistance, subgroup analysis from 2000 to 2018 showed a significant increase in ciprofloxacin resistance. Conclusion: Monitoring and evaluating antibiotic-sensitivity patterns and preparation of reliable antibiotic strategies may lead to better outcomes for inhibition and control of E. coli infections in different regions of the world.

25 April 2017 in Frontiers in Microbiology
Verified
Journal Article
Open access
Mohammad Javad NasiriMohammad Javad Nasiri
Mohammad Javad Nasiri
MHMehri Haeili
Mehri Haeili
MGMona Ghazi
Mona Ghazi
HGHossein Goudarzi
Hossein Goudarzi
APAli Pormohammad
Ali Pormohammad
MFMohammad M. Feizabadi
Mohammad M. Feizabadi
Infectious diseases caused by clinically important Mycobacteria continue to be an important public health problem worldwide primarily due to emergence of drug resistance crisis. In recent years, the control of tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (MTB), is hampered by the emergence of multidrug resistance (MDR), defined as resistance to at least isoniazid (INH) and rifampicin (RIF), two key drugs in the treatment of the disease. Despite the availability of curative anti-TB therapy, inappropriate and inadequate treatment has allowed MTB to acquire resistance to the most important anti-TB drugs. Likewise, for most mycobacteria other than MTB, the outcome of drug treatment is poor and is likely related to the high levels of antibiotic resistance. Thus, a better knowledge of the underlying mechanisms of drug resistance in mycobacteria could aid not only to select the best therapeutic options but also to develop novel drugs that can overwhelm the existing resist¬ance mechanisms. In this article, we review the distinctive mechanisms of antibiotic resistance in mycobacteria.

14 October 2019 in Gut Pathogens
Verified
Journal Article
Open access
PDF file
PJParnian Jamshidi
Parnian Jamshidi
SHSaba Hasanzadeh
Saba Hasanzadeh
ATAzin Tahvildari
Azin Tahvildari
YFYeganeh Farsi
Yeganeh Farsi
MAMahta Arbabi
Mahta Arbabi
Mohammad Javad NasiriMohammad Javad Nasiri
Mohammad Javad Nasiri
Introduction: Type 1 diabetes (T1D) is the second most common autoimmune disease among children. There is evidence suggesting that dysbiosis of some gut colonizing bacteria are associated with the pathogenesis of T1D. However, these studies are still controversial and a systematic review was conducted to evaluate the association between gut microbiota and T1D.Methods: A systematic search was carried out in Medline (Via Pubmed) and Embase from January 2000 to January 2019 for all original cross-sectional, cohort, case–control or nested case–control studies investigating the association between gut microbiota and T1D.Results: Of 568 articles identified, 26 studies met the inclusion criteria. The total population study of these articles consists of 2600 children (under 18 years old) and 189 adults. Among the included studies, 24 articles confirmed the association between gut microbiota dysbiosis and T1D. The most common bacterial alterations in T1D patients includedBacteroidesspp.,Streptococcusspp.,Clostridiumspp.,Bifidobacteriumspp.,Prevotellaspp.,Staphylococcusspp.,Blautiaspp.,Faecalibacteriumspp.,Roseburiaspp., andLactobacillusspp.Conclusion: Our study showed a significant association between alterations in intestinal microbial composition and T1D; however, in some articles, it is not clear which one happens first. Investigation of altered gut microbiota can help in the early detection of T1D before seropositivity. Targeted microbiome modulation can be a novel potential therapeutic strategy.

1 September 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
TATaher Azimi
Taher Azimi
MMMehrdad Mosadegh
Mehrdad Mosadegh
Mohammad Javad NasiriMohammad Javad Nasiri
Mohammad Javad Nasiri
SSSahar Sabour
Sahar Sabour
SKSamira Karimaei
Samira Karimaei
ANAhmad Nasser
Ahmad Nasser
Mycobacterial infections are considered to a serious challenge of medicine, and the emergence of MDR and XDR tuberculosis is a serious public health problem. Tuberculosis can cause high morbidity and mortality around the world, particularly in developing countries. The emergence of drug-resistant Mycobacterium infection following limited therapeutic technologies coupled with the serious worldwide tuberculosis epidemic has adversely affected control programs, thus necessitating the study of the role bacteriophages in the treatment of mycobacterial infection. Bacteriophages are viruses that are isolated from several ecological specimens and do not exert adverse effects on patients. Phage therapy can be considered as a significant alternative to antibiotics for treating MDR and XDR mycobacterial infections. The useful ability of bacteriophages to kill Mycobacterium spp has been explored by numerous research studies that have attempted to investigate the phage therapy as a novel therapeutic/diagnosis approach to mycobacterial infections. However, there are restricted data about phage therapy for treating mycobacterial infections. This review presents comprehensive data about phage therapy in the treatment of mycobacterial infection, specifically tuberculosis disease.

11 August 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SKSeyyedeh Neda Kazemi
Seyyedeh Neda Kazemi
BHBahareh Hajikhani
Bahareh Hajikhani
HDHamidreza Didar
Hamidreza Didar
SHSareh Sadat Hosseini
Sareh Sadat Hosseini
SHSara Haddadi
Sara Haddadi
Mohammad Javad NasiriMohammad Javad Nasiri
Mohammad Javad Nasiri
Introduction: The association between Coronavirus Disease 2019 (COVID-19) and abortion has been debated since the beginning of the COVID-19 pandemic. We aimed to conduct this systematic review to understand better the potential effects of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) on fetal loss in infected mothers presented with abortion following this infection. Methods: We included articles published in PubMed/Medline, Web of Science, clinicaltrials.gov, and Embase databases in 2019 and 2020 through a comprehensive search via appropriate keywords, including COVID-19 and abortion synonyms. All studies with the abortion data in COVID-19 confirmed pregnant females were collected. Results: Out of 208 potentially relevant articles, 11 articles were eligible to include in the systematic review. The included reports were published because of the following reasons: (1) First-trimester miscarriage; (2) Late miscarriage; (3) complication of COVID-19 infection in pregnancy; (4) COVID-19 disease in artificial pregnancy. First-trimester abortion was found in 5 studies, and second-trimester abortion in 7 studies. Two patients acquired infection during the hospital stay while they were referred for abortion. Reports related to abortion in pregnant females with COVID-19 show that most miscarriages due to COVID-19 in the first trimester were due to placental insufficiency. Conclusions: There is an increased risk of abortion in mothers with a positive test result of SARS-CoV-2, which several case reports and case series have identified during the pandemic. Placental inflammation during the viral infection may result in fetal growth retardation and induce abortion. There has not been any consistent evidence of vertical transmission of the virus from mother to fetus, which requires further investigation.

4 April 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
TSTahereh Sabaghian
Tahereh Sabaghian
AKAmir Behnam Kharazmi
Amir Behnam Kharazmi
AAAli Ansari
Ali Ansari
FOFatemeh Omidi
Fatemeh Omidi
SKSeyyedeh Neda Kazemi
Seyyedeh Neda Kazemi
MMMehdi Mirsaeidi
Mehdi Mirsaeidi
Introduction: Acute kidney injury (AKI) has been associated with an increased mortality rate among hospitalized patients with Coronavirus disease 2019 (COVID-19). The current review aimed to evaluate the symptoms, complications, and treatments performed to manage AKI in patients with COVID-19.Methods: We searched PubMed/Medline, Web of Science, and Embase for the relevant scientific literature published up to February 1, 2022. The following keywords were used: “COVID-19”, “SARS-CoV-2”, and “Acute kidney injury”.Results: Forty-four studies with a total number of 114 COVID-19 patients with AKI (Mean age: 53.6 years) were included in our systematic review. The most common comorbidities in patients with COVID-19 suffering from AKI were the history of diabetes, hypertension, and hyperlipidemia. Twelve out of the 44 included studies reported a history of chronic kidney disease (CKD) in this group of patients. Focal segmental glomerulosclerosis (FSGS) and acute tubular necrosis (ATN) were the most common pathological evidence. The average length of hospital stay was 19 days, and the average duration of need for mechanical ventilation was 3 days.Conclusions: The current systematic review shows that AKI frequently complicates the course of COVID-19 hospitalizations and is associated with increased severity of illness, prolonged duration of hospitalization, and poor prognosis. Given the extent of the adverse impact of AKI, early detection of comorbidities and renal complications is essential to improve the outcomes of COVID-19 patients.